Studies have shown that MDSCs from patients with urothelial and renal cell carcinoma express CCR8 (the CCL1 receptor), and tumor-derived CCL1 promotes the accumulation of MDSCs in both the peripheral blood and tumor tissue [58]. Here, CCR8 is linked to neoplasm.